Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27204398 | 0.85 | CPB2 (0.49) | NTSR2NTSR1CPB2 | |
| SCHEMBL31538181 | 0.85 | CPB2 (0.49) | NTSR2NTSR1CPB2 | |
| SCHEMBL27164798 | 0.85 | CPB2 (0.49) | NTSR2NTSR1CPB2 | |
| SCHEMBL31275624 | 0.85 | CPB2 (0.44) | F2NTSR2NTSR1CPB2 | |
| SCHEMBL30335748 | 0.85 | CPB2 (0.49) | NTSR2NTSR1CPB2 | |
| SCHEMBL2119466 | 0.85 | BACE1 (0.45) | F2CTSDBACE1NTSR2NTSR1 | |
| SCHEMBL2119473 | 0.85 | BACE1 (0.45) | F2CTSDBACE1NTSR2NTSR1 | |
| SCHEMBL2191312 | 0.85 | FURIN (0.43) | FURINBACE1 | |
| SCHEMBL2191316 | 0.85 | FURIN (0.43) | FURINBACE1 | |
| SCHEMBL31276210 | 0.82 | CPB2 (0.46) | F2NMT2NMT1NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | FURIN 129/4885PCSK6 1135/4885F2 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.